Telix finds a bigger radiopharma platform in US$1.65 billion ITM deal
Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.
- US$1.65 billion upfront acquisition, including approximately US$1.25 billion in Telix shares
- ITM shareholders expected to own 23.7% of Telix at completion
- Up to US$700 million in milestone payments tied to ITM-11 approvals and sales
- ITM generated US$273 million revenue in 2025 and supplies lutetium-177 globally
- FDA review of ITM-11 remains blocked on manufacturing and facility issues
Telix targets commercial scale through ITM acquisition
Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX) is making its largest strategic move yet, agreeing to acquire 100% of ITM Isotope Technologies Munich SE in a proposed US$1.65 billion transaction. The combination would put a commercial-scale radioisotope manufacturing business alongside Telix’s precision diagnostics and late-stage therapeutic programs, creating a company spanning isotope production, drug development, manufacturing and distribution.
Share consideration will reshape Telix’s ownership
The headline price is not a cash cheque. Telix expects to pay approximately US$1.25 billion in 105.8 million new shares priced at US$11.841 each, while assuming US$302 million of net debt and accounting for US$96 million in management equity rollover and transaction expenses, subject to closing adjustments. ITM shareholders would own about 23.7% of Telix shares on issue after completion, leaving existing Telix shareholders with approximately 76.3%. The sellers’ shares will be released as Nasdaq-listed American depositary receipts after escrow periods of up to 15 months.
ITM adds a profitable isotope platform
ITM reported audited 2025 revenue of US$273 million, up from US$70 million in 2021, according to the transaction materials. It operates two GMP manufacturing sites, supplies more than 400 destinations each week across over 65 countries and has long-term access to irradiation capacity through its Isogen agreement with Bruce Power reactors in Canada. Its core product is non-carrier-added lutetium-177, a critical isotope for targeted radionuclide therapies, with expansion plans covering actinium-225 and terbium-161.
The financial attraction is the manufacturing arm rather than a purely speculative drug pipeline. ITM’s manufacturing division generated annualised adjusted EBITDA of US$106 million in the first half of 2026, according to unaudited figures, while Telix says ITM is expected to contribute positively to group EBITDA from 2027. The combined group is estimated to generate more than US$1.3 billion of 2026 revenue and income, although that figure is based on management estimates. Telix is also targeting US$50 million of additional synergies over the first two years, excluding one-off integration costs.
ITM-11 offers upside but remains an FDA-dependent asset
The therapeutic prize is ITM-11, a lutetium-177 treatment candidate for gastroenteropancreatic neuroendocrine tumours. In the Phase 3 COMPETE trial, ITM-11 produced median progression-free survival of 23.9 months versus 14.1 months for everolimus, with a stratified hazard ratio of 0.673. The trial included 309 patients, and the filing reports Grade 3 or 4 treatment-related adverse events in 18% of ITM-11 patients compared with 40% for everolimus. Those results are promising, but the candidate is not approved anywhere.
The immediate regulatory obstacle is clear. The FDA issued a complete response letter on 7 August 2026 citing chemistry, manufacturing and controls and third-party facility inspection matters. Telix and ITM say no clinical safety or efficacy deficiencies were identified and no additional clinical or non-clinical data were requested, but ITM must still address the manufacturing issues and resubmit its application, or agree a satisfactory path to resubmission, before completion. The deal attaches up to US$250 million of regulatory milestones to approvals across three indications, plus as much as US$450 million linked to ITM-11 global sales above US$150 million in 2030.
November vote is the first decisive test
Telix expects to convene an extraordinary general meeting in November, with completion targeted by the end of 2026 if shareholder, regulatory and other closing conditions are met. Approval of the upfront share issue is a condition of the transaction; failure could trigger a US$5 million fee to ITM as well as transaction costs already incurred. For shareholders, the central trade-off is unusually stark: the acquisition offers a faster path to manufacturing cash flow and therapeutic scale, but it also transfers a meaningful slice of Telix to ITM’s owners before the FDA pathway and promised synergies have been fully delivered.
Bottom Line?
The deal’s value now turns on execution: Telix must secure shareholder approval, clear ITM-11’s manufacturing hurdles and prove that a larger radiopharmaceutical platform can deliver the projected EBITDA uplift without allowing dilution and integration costs to overwhelm it.
Questions in the middle?
- Can ITM resolve the FDA’s manufacturing and third-party facility objections quickly enough to support the proposed milestone timetable?
- Will the US$50 million synergy target survive the integration of two complex manufacturing, clinical and commercial organisations?
- How will Telix’s share price and capital allocation respond once ITM shareholders’ escrow restrictions begin to expire?
